Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
177 Results for "
nk1
" in MedChemExpress (MCE) Product Catalog:
Products (177)
177 Results for "nk1" in MCE Product Catalog:
33
33
Research Areas:
4
Target:
Research Areas:
Netupitant (CID-6451149) is a highly potent, selective and orally active neurokinin-1 (NK1) receptor antagonist with a Ki of 0.95 nM for hNK1 in CHO cells. Netupitant has antiemetic affect [1] .
3
3 Cited Publications
Cat. No.: HY-P0187
CAS No.: 106128-89-6
Target:
Research Areas:
3
3 Cited Publications
Cat. No.: HY-W013375
CAS No.: 76721-89-6
Target:
Research Areas:
Thiorphan is a selective neprilysin (NEP) inhibitor with an IC50 of 6.9 nM. Thiorphan competitively binds to NEP and blocks its activity, preventing the degradation of neuropeptides such as substance P (SP) and neurokinin NKA. In the field of neonatal brain injury research, Thiorphan can increase the levels of SP and NKA, activate NK1 and NK2 receptors and downstream transduction pathways, and inhibit excessive activation of NMDA receptors. Thus, Thiorphan can protect neocortical neurons from excitotoxic cell death. Thiorphan may also inhibit NEP from enhancing bronchoconstriction and can be used in the study of respiratory diseases [1] .
1
1 Cited Publications
Target:
Research Areas:
L-732138 is a selective, potent and competitive neurokinin-1 (NK-1) receptor antagonist with an IC50 of 2.3 nM. L-732138 has 200-fold more potent in cloned human NK-1 receptors than cloned rat NK-1 receptors, and has > 1000-fold more potent than human NK-2 and NK-3 receptors. L-732138 can reduce hyperalgesia and has antitumor action [1] .
1
1 Cited Publications
Target:
Research Areas:
Maropitant is an orally active NK1 receptor antagonist. Maropitant prevents vomiting and inhibits ulcerative dermatitis [1] .
1
1 Cited Publications
Cat. No.: HY-P0061A
CAS No.: 849479-74-9
Synonyms: RC-160 acetate; BMY-41606 acetate
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
L-733060 hydrochloride is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 hydrochloride mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 hydrochloride blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 hydrochloride reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 hydrochloride can be used for the study of chronic orofacial pain [1] .
1
Target:
Research Areas:
1
1 Cited Publications
Synonyms: Pronetupitant chloride monohydrochloride
Target:
Research Areas:
Fosnetupitant chloride monohydrochloride (Pronetupitant chloride monohydrochloride) is an NK1 antagonist with pKi values of 9.5, 6.1 for human NK1 and NK3 receptor, respectively. Fosnetupitant chloride monohydrochloride is a methylene phosphate prodrug of Netupitant [1].
1
1 Cited Publications
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-18006
CAS No.: 177707-12-9
Target:
Neurokinin Receptor Wnt Bcl-2 Family β-catenin Cyclin G-associated Kinase (GAK) VEGFR Caspase Cadherin Apoptosis
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
NKP608 is a non-peptidic derivative of 4-aminopiperidine, a highly selective, orally active, neurokinin-1 (NK1) receptor antagonist with IC50 of 2.6 nM. NKP608 is active both in vitro and in vivo, showing extremely low affinity for NK2, NK3 receptors. NKP608 exerts its effects by blocking the NK₁ receptor, regulate cell proliferation and apoptosis, affect neurotransmitter functions and gastric mucosal repair mechanisms, and suppress the Wnt/β-catenin pathway in antitumor research. NKP608 is applicable to research related to various diseases, including cough, anxiety disorders, depression, gastric mucosal injury, and colorectal cancer [1] .
1
1 Cited Publications
Cat. No.: HY-P1722
CAS No.: 129176-97-2
Target:
Research Areas:
Synonyms: NT-814; BAY3427080
Target:
Research Areas:
Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause [1] .
Cat. No.: HY-P99143
Target:
Research Areas:
Cat. No.: HY-16732
CAS No.: 622370-35-8
Synonyms: VLY-686; LY686017
Target:
Research Areas:
Tradipitant (VLY-686) is a neurokinin-1 (NK-1) antagonist.
Cat. No.: HY-P1192
CAS No.: 133156-06-6
Target:
Research Areas:
Cat. No.: HY-108483
CAS No.: 135911-02-3
Target:
Research Areas:
RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation [1].
Target:
Research Areas:
NK1 receptor antagonist 2 is a neurokinin 1 (NK1) receptor antagonist. NK1 receptor antagonist 2 is applicable to research related to tinnitus and hearing loss [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
